Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.
List view / Grid view
Filter the results
A team has successfully created a new method to artificially produce FE399, a compound known to induce apoptosis in cancer cells.
Pre-clinical testing of the COVIDTRAP™ (STI-4398) protein and STI-1499 antibody reveal they can inhibit SARS-CoV-2 from infecting cells.
Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
Application note: High-throughput sialylation screening in combination with titer monitoring for expediting clone selection in cell-line development
Glycosylation is one of the most important post-translational modifications when developing new biologics. It has a considerable impact on product performance and variability and is therefore a critical quality attribute (CQA), influencing product safety and efficacy.
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
If not correctly assessed, drug candidates with undesirable safety issues may progress through clinical development, resulting in costly failures later in the development process. Given that many drugs fail in clinical trials due to nephrotoxicity, this article describes the importance of understanding kidney transporter function in drug development, how current…
Here, Sheraz Gul highlights some encouraging displays of industry co-operation that aim to counter the global threat posed by COVID-19.
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
According to a new study, apolipoprotein A-I binding protein restricts HIV-1 replication by targeting lipid rafts and reducing virus-cell fusion.
Scientists have produced hundreds of organoids which they say could be produced on a large-scale as a low-cost tissue model to help research and test new medulloblastoma therapies.
Scientists have created the first lab-dish models of the cellular clock, where each 'tick' stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue.
It is said that, on average, it takes a new drug 12 years to go from research lab to patient, with many thousands of candidates discarded along the way. Can artificial intelligence (AI) help to speed things up? Sheraz Gul and Alp Sahin provide an overview of an AI approach…
Energy metabolism drives everything we do, so it is no surprise that the more we discover about these metabolic processes, the more we observe seamless integration with all core cellular functions.